以克隆载体为自杀载体快速构建布鲁氏菌的无痕缺失突变株

构建突变株是病原微生物致病机理研究的重要手段。以往研究中布鲁氏菌的无痕缺失突变株都采用传统的自杀载体来构建,效率低下。首先对布鲁氏菌的电击转化条件进行了优化,然后选择含有反向筛选基因sacB的pEX18Gm质粒作为自杀载体,构建了缺失Ⅳ型启动子区的布鲁氏菌无痕缺失突变株。这不仅为构建布鲁氏菌的突变株提供了一个快速有效的技术平台,也为深入研究Ⅳ型分泌系统的功能奠定了基础。     

肺炎支原体双蛋白多抗原表位表达载体的构建

目的构建肺炎支原体(Mp)双蛋白多特异抗原表位表达载体,提高重组蛋白抗原的敏感性。方法应用生物信息学方法筛选Mp P116粘附蛋白抗原表位序列,PCR点突变技术获取P116蛋白基因片段,与pMD-T载体重组,转入大肠埃希菌JM109,通过限制性酶切图谱和基因序列分析鉴定重组质粒。酶切回收P116基因片段与pGEX 6P-1-P1 DNA重组,转入大肠埃希菌JM109菌株。用Glutathione Sepharose 4B纯化重组蛋白,SDS-PAGE分析表达产物的相对分子量,用Mp免疫血清进行免疫印迹试验,鉴定重组蛋白的免疫原性。结果 PCR点突变扩增Mp黏附蛋白P116的基因片段为597 bp,该基因片段与已知的基因库序列分析比较,除两个突变位点由UAG突变为UGG外,其余核苷酸序列同源性为100%。SDS-PAGE分析多表位重组蛋白相对分子质量(Mr)为77.8 kDa。免疫印迹结果显示,Mp兔多价血清能与纯化的78KDa的重组蛋白发生免疫反应。结论本研究成功构建了Mp双蛋白多表位的表达载体。该表达载体表达的重组蛋白具有Mp特异的免疫反应性。重组蛋白的敏感性有待进一步鉴定。     

利用T载体克隆快速构建布鲁氏菌缺失突变株

目的：建立一种基于T载体快速克隆构建布鲁氏菌突变株的方法,提高布鲁氏菌突变株构建的效率;方法：采用融合PCR的方法,将待缺失基因上下游的同源臂与卡那霉素抗性基因融合起来,构建突变盒,然后将突变盒直接与T载体连接,构建突变载体,将载体转入布鲁氏菌感受态细胞并筛选抗性克隆,进而获得布鲁氏菌的缺失突变株。结果：结合融合PCR和T载体快速克隆,能够在48h之内构建好突变载体,与传统的酶切连接相比,效率高、周期短。结论：基于T载体快速克隆是一种非常高效的构建突变株的方法,为布鲁氏菌突变株的构建提供了一种新方法。     

维氏气单胞菌hfq基因敲除菌株的构建及鉴定

RNA分子伴侣蛋白Hfq是细菌中普遍存在的全局调控因子,对于细菌的生长增殖、毒性和逆境耐受等都有重要影响。维氏气单胞菌(Aeromonas veronii)是一种新型人—鱼共患条件致病菌,会在水产养殖中造成巨大危害。本研究从维氏气单胞菌基因组DNA中扩增hfq基因上、下游序列,连接到pRE112质粒中,构建敲除质粒pRE112-Δhfq,通过接合转移将敲除质粒从大肠杆菌感受态转入维氏气单胞菌后,基于同源重组原理,利用蔗糖压力筛选得到hfq基因敲除的维氏气单胞菌突变株C4-Δhfq。生长曲线分析表明,hfq基因敲除显著延缓维氏气单胞菌的生长速率,同时,回补hfq使细菌恢复生长。本研究获得的hfq基因敲除菌株,可为进一步研究维氏气单胞菌中Hfq调控因子的功能及其调控机制提供一定帮助。     

表位疫苗研究进展

表位疫苗是用抗原表位制备的疫苗,是近年来新兴的一种疫苗研制技术,也是今后最具开发前景的疫苗技术之一,在肿瘤、病毒等疾病的防治中有着自身独特的优势.详细阐述了T表位和B表位的筛选和鉴定方法、表位疫苗的载体研究及表位疫苗在肿瘤、病毒和微生物感染中的应用等,对表位疫苗的最新研究进展进行了综述.     

犬种布鲁氏菌ZG株单克隆抗体4H3抗原模拟表位的筛选及分析

【背景】目前犬布鲁氏菌病诊断存在一定的困难。【目的】筛选并研究犬种布鲁氏菌单克隆抗体4H3株的特异性抗原表位。【方法】利用噬菌体肽库展示技术,以犬种布鲁氏菌单克隆抗体4H3株作为靶分子,包被酶标板,用12肽随机肽库经过3轮生物淘洗程序进行筛选。经过3轮筛选后,噬菌体产出率从5.00×10^-7增加到9.84×10^-6,假阳性率逐轮降低。从第3轮筛选的阳性克隆中随机挑取14个进行增殖,提取基因组DNA,进行测序分析;并通过iELISA和cELISA检测阳性克隆的亲和性和特异性。【结果】14株阳性单克隆噬菌体共出现3种不同的短肽序列,分别是KMSIRHPIRLPI、ILRRRRKRIIQI和QRIHMRLTTQS;iELISA结果表明3种短肽序列与单克隆抗体的亲和性依次为KMSIRHPIRLPI>ILRRRRKRIIQI>QRIHMRLTTQS;cELISA结果显示短肽KMSIRHPIRLPI和ILRRRRKRIIQI特异性较强。对亲和性较强、特异性较高的2条短肽KMSIRHPIRLPI和ILRRRRKRIIQI展开具体分析,比对分析表...     

含CD自杀基因腺病毒载体的构建及其应用

构建了含ＣＭＶ启动子、大肠杆菌胞嘧啶脱氨酶（ｃｄ）基因的复制缺陷型重组腺病毒载体（ＡｄＣＭＶＣＤ）。经Ｓｏｕｔｈｅｒｎ杂交和ＲＴ－ＰＣＲ鉴定证实,ｃｄ基因已克隆进入ＡｄＣＭＶＣＤ,并在受染细胞中表达。经氯化铯密度梯度离心法纯化的病毒滴度达１×１０１５ｐｆｕ／Ｌ。经１００ｍ．ｏ．ｉ．的ＡｄＣＭＶＣＤ感染的ＨｅＬａ和Ｃ６细胞株在１００μｍｏｌ／Ｌ５ＦＣ处理后,细胞存活率＜２０％。同时也观察到ＡｄＣＭＶＣＤ／５ＦＣ系统有很强的旁杀伤效应,将３．３％的ＡｄＣＭＶＣＤ受染细胞与９６．７％的野生型细胞混合,经５０μｍｏｌ／Ｌ５ＦＣ处理后,＞６０％的细胞被杀死。ＡｄＣＭＶＣＤ／５ＦＣ系统的建立为肿瘤基因治疗的研究提供了新的手段。     

猪流感病毒抗原表位基因表达载体构建与免疫原性分析

根据猪流感病毒血凝素蛋白基因(Heamuglutinine, HA)的核苷酸序列, 设计、筛选HA蛋白氨基酸序列的主要表位多肽4个, 将4个片段以柔性连接串联成模拟蛋白, 核苷酸约为300 bp, 体外扩增该模拟蛋白基因, 插入到原核表达载体pET30a(+)中, 转染宿主菌诱导表达, 结果获得分子量为20 kD的表达蛋白, 该蛋白可与抗His-tag抗体、抗猪流感病毒H1N1、H3N2亚型高免血清发生免疫学反应。纯化后免疫小鼠, ELISA及血凝抑制(Heamuglutinine inhibitor, HI)试验检测, 小鼠产生针对多肽抗原的血清抗体, 同时还可检测到H1N1、H3N2亚型SIV血凝抗体。流氏细胞仪检测免疫组外周血淋巴细胞高于对照组, 说明该模拟蛋白具有与H1N1、H3N2亚型猪流感病毒相似的免疫原性及反应原性, 为H1N1、H3N2血清亚型猪流感病毒疫苗研制提供了新手段。     

猪流感病毒抗原表位基因表达载体构建与免疫原性分析

根据猪流感病毒血凝素蛋白基因(Heamuglutinine, HA)的核苷酸序列, 设计、筛选HA蛋白氨基酸序列的主要表位多肽4个, 将4个片段以柔性连接串联成模拟蛋白, 核苷酸约为300 bp, 体外扩增该模拟蛋白基因, 插入到原核表达载体pET30a(+)中, 转染宿主菌诱导表达, 结果获得分子量为20 kD的表达蛋白, 该蛋白可与抗His-tag抗体、抗猪流感病毒H1N1、H3N2亚型高免血清发生免疫学反应。纯化后免疫小鼠, ELISA及血凝抑制(Heamuglutinine inhibitor, HI)试验检测, 小鼠产生针对多肽抗原的血清抗体, 同时还可检测到H1N1、H3N2亚型SIV血凝抗体。流氏细胞仪检测免疫组外周血淋巴细胞高于对照组, 说明该模拟蛋白具有与H1N1、H3N2亚型猪流感病毒相似的免疫原性及反应原性, 为H1N1、H3N2血清亚型猪流感病毒疫苗研制提供了新手段。     

A、O型FMDVT／B细胞抗原表位融合基因合成及植物表达载体构建

人工合成A、O型FMDV的7个细胞表位基因,应用套叠PCR将其中5个T细胞表位基因融合为T,2个B细胞表位基因融合为B,分别克隆进pMD-18T载体,再利用同尾酶的酶切及连接构建了不同组合的克隆载体(pMD-BT/BTT),然后将克隆载体改造为中间载体(pMD-xsB/xsT/xsBT/xsBTT),最终获得4个重组植物表达载体(pBI-xsB/xsT/xsBT/xsBTT).这为进行热研2号柱花草遗传转化及进一步研究同型与异型FMDV之间多表住基因的不同融合方式的免疫效果奠定了基础.为口蹄疫可饲植物疫苗的应用研究提供借鉴.     

pUC19K质粒的构建及其在布鲁氏菌突变株构建中的应用

突变株的构建是细菌基因功能研究的前提。本研究构建了一个可用于布鲁氏菌突变株构建的自杀质粒。在pUC19质粒的多克隆位点插入卡那霉素抗性基因,在该基因两侧添加多个酶切位点,构建成为pUC19K。利用该质粒,我们构建了布鲁氏菌外膜蛋白Omp25基因的突变株。结果表明,利用该自杀质粒,通过一轮筛选即可得到目标基因被抗性基因替换的突变株。pUC19K质粒的构建及成功应用,为布鲁氏菌突变株的构建提供了一个快速有效的手段,也为布鲁氏菌的基因功能研究奠定了基础。     

Infection by Brucella melitensis or Brucella papionis modifies essential physiological functions of human trophoblasts

Brucellosis is a zoonosis caused by bacteria of the Brucella genus. In ruminants, brucellosis causes abortion, followed by chronic infection and secretion of bacteria in milk. In humans, it usually presents as flu‐like symptoms, with serious complications if untreated. Epidemiological studies have only recently established that brucellosis can also cause pregnancy complications in women, but the pathogenic mechanisms are unknown. Pioneering studies in ruminants showed that Brucella infect trophoblasts and then colonise the placenta where they grow to high density. A recent study showed that the main zoonotic Brucella species can infect human cytotrophoblasts (CTB) and extravillous trophoblasts (EVT). In this work, we show that Brucella papionis (associated with stillbirth in primates) also infects human trophoblasts. However, it replicates actively in CTB, whereas its replication is very restricted within EVT. We also observed alteration of several trophoblastic functions upon infection by B. papionis or Brucella melitensis (the most prevalent species in human brucellosis). Infection altered the production of hormones, the ability of CTB to form syncytiotrophoblasts, and the invasion capacity of EVT. We also found that infection can spread between different types of trophoblasts. These findings constitute a new step in understanding how Brucella infection causes adverse pregnancy outcomes.     

Brucella melitensis 16MΔhfq attenuation confers protection against wild‐type challenge in BALB/c mice

Brucellosis is a globally distributed zoonotic disease that causes animal and human diseases. Although effective, the current Brucella vaccines (Rev.1 and M5‐90) have several drawbacks. The first involves residual virulence for animals and humans and the second is the inability to differentiate natural infection from that caused by vaccination. Therefore, Brucella melitensis 16M hfq mutant (16MΔhfq) was constructed to overcome these drawbacks. Similarly to Rev.1 and M5‐90, 16MΔhfq reduces survival in macrophages and mice and induces strong protective immunity in BALB/c mice. Moreover, these vaccines elicit anti‐Brucella‐specific IgG1 and IgG2a subtype responses and induce secretion of gamma interferon and interleukin‐4. The Hfq antigen also allows serological differentiation between infected and vaccinated animals. These results show that 16MΔhfq is an ideal live attenuated vaccine candidate against virulent Brucella melitensis 16M infection. It will be further evaluated in sheep.     

Brucella melitensis B115-based complement fixation test to detect antibodies induced by Brucella rough strains

Aims:  To assess the efficiency of a Brucella melitensis B115 rough strain, naturally devoid of anticomplementary activity, used as antigen in a complement fixation test (CFT) to detect antibodies induced by Brucella strains with rough phenotype, such as Brucella abortus RB51, Brucella ovis and Brucella canis .
Methods and Results:  Complement fixation testing was performed on sera from RB51-vaccinated cattle and buffaloes, B. ovis -infected sheep and B. canis -infected dogs using B115, RB51 and the hot saline extract (HSE) as antigens. The B115-based CFT proved highly sensitive and specific in detecting rough antibodies and its efficiency was comparable with that of RB51 and HSE-based CFT.
Conclusions:  Brucella melitensis B115 can be successfully used as an antigen in CFT to detect antibodies induced by Brucella rough strains.
Significance and Impact of the Study:  Brucella melitensis B115 antigen may represent an improvement over Brucella rough strains for Brucella antibody detection by CFT, thus enhancing the efficiency of brucellosis surveillance systems. Owing to the absence of anticomplementary activity, it does not require particular growth conditions or modifications and can be accurately standardized. The B115-based CFT may constitute a suitable supplementary test for the diagnosis of human infections owing to rough Brucellae .     

Localization and characterization of a specific linear epitope of the Brucella DnaK protein

We have previously produced and characterized four monoclonal antibodies to the Brucella DnaK protein which were derived from mice infected with B. melitensis or immunized with the B. melitensis cell wall fraction. By use of a recombinant DNA technique, we have localized a linear epitope, recognized by two of these monoclonal antibodies (V78/07B01/G11 and V78/09D04/D08), in the last 21 amino acids of the C-terminal region of the Brucella DnaK protein. The C-terminal region has been reported to be the most variable region among DnaK proteins. The two other monoclonal antibodies (A53/09G03/D02 and A53/01C10/A10) failed to react with the recombinant clones and might recognize discontinuous epitopes of the Brucella DnaK protein. The four monoclonal antibodies reacted with all recognized Brucella species and biovars in immunoblotting after SDS-PAGE. Monoclonal antibodies V78/07B01/G11 and V78/09D04/D08 did not react with reported cross-reacting bacteria nor with bacteria of the α-2 subdivision of the class Proteobacteria for which a close genetic relationship with Brucella spp. has been reported. However, monoclonal antibodies A53/09G03/D02 and A53/01C10/A10 reacted with Phyllobacterium rubiacearum and/or Ochrobactrum anthropi, both bacteria of the α-2 subdivision of the class Proteobacteria. The Brucella genus DnaK specific epitopes could be of importance for diagnostic purposes.     

羊布鲁氏菌的分泌蛋白质组分析

分泌蛋白是指那些分泌到细胞外的蛋白质。布鲁氏菌的分泌蛋白可能介导了病原与宿主之间的相互作用, 在布鲁氏菌的毒力方面发挥一定的作用, 但是研究方法的局限性限制了分泌蛋白的研究。本文报道了利用蛋白质组的方法来寻找羊布鲁氏菌的分泌蛋白。首先用TCA-丙酮法提取布鲁氏菌培养上清中的分泌蛋白, 双向电泳进行分离, 然后用质谱来鉴定这些蛋白, 最终鉴定到40种蛋白。通过生物信息学分析, 发现这些蛋白主要是ABC转运系统的底物结合蛋白、外膜蛋白和热休克蛋白。这些蛋白的识别不仅有助于对布鲁氏菌致病机制的理解, 而且也可为     

Antibiotic treatment induces an increase of the specific antibody levels in Brucella melitensis infected mice

Abstract The effects of doxycycline (DOX) and streptomycin (SM) treatment of Brucella melitensis infected mice on humoral immune response were examined. In female BALB/c mice, DOX was administered at a dose of 50 mg/kg/12 h, for 21 or 45 consecutive days, alone or combined with SM (10 mg/kg/12 h) for 14 days. All treatments induced a significant increase in specific IgG levels (ELISA and CIEP) against LPS and cytosolic antigens of Brucella during treatment. This was not related with therapeutic failure or relapse since all treatments induced a significant reduction in the degree of infection.     

羊布鲁氏菌非编码小RNA分子BSR-2的预测与鉴定

利用RT-PCR和RACE等方法对生物信息学预测的羊布鲁氏菌非编码小RNA(smallnon-codingRNA,sRNA)BSR-2进行了实验鉴定,并通过分析BSR-2在胞内生存缺陷株中的转录情况以及预测BSR-2的靶标基因对BSR-2的功能进行初步探讨.RT-PCR结果表明,BSR-2在羊布鲁氏菌的总RNA中存在转录本,而且在不同的应激条件下转录水平不同.RACE结果表明,BSR-2长224nt,位于Ⅱ号染色体的BMEII0742和BMEII0743之间的基因间区.进一步的实验结果表明,BSR-2可能与布鲁氏菌的胞内生存能力相关.